tesamorelin + CJC-1295 + ipamorelin vs cjc+ipa blend
updated
tesamorelin + CJC-1295 + ipamorelin (tier F) vs cjc+ipa blend (tier A): what each is, why each got its grade, half-life and source counts side by side.
tesamorelin + CJC-1295 + ipamorelin · tier F
a three-peptide GH-axis blend with no located direct study, whose CJC variant, component forms, and ratio must be known before even its duration can be described.
tier rationale
F-tier applies while formulation identity is unresolved and no fixed-blend safety study is located. The same CJC label can refer to molecules whose duration differs by orders of magnitude, tesamorelin's approval does not transfer to a combination, and no located animal or human study tests all three together. Exact verified forms and ratios could support a molecule-level reassessment, but they would not create a clinical outcome or safety record for the blend.
cjc+ipa blend · tier A
clinic-standard GH-axis pairing. cjc-1295 + ipamorelin. receptor logic first, blend trial evidence still thin.
tier rationale
A-tier reflects receptor-pair logic and component-level pharmacology. Not S-tier because direct fixed-blend outcome trials and long-term safety data are missing. The blend is plausible, widely used, and still less proven than the clinic market makes it sound.
at a glance
| tesamorelin + CJC-1295 + ipamorelin | cjc+ipa blend | |
|---|---|---|
| tier | F | A |
| category | gh / growth | gh / growth |
| sources | 9 | 19 |
| claims evaluated | 5 | 6 |
| half-life | blend unknown; 5.8 to 8.1 days belongs only to confirmed CJC-1295 with DAC | CJC-1295: 30 min |
| dosing data | yes | yes |
reptides grades the research record and cites the literature behind every call. research reference only; not medical advice.